Daiichi Sankyo Company, Limited (TYO:4568)
Japan
· Delayed Price · Currency is JPY 3,214.00
+114.00 (3.68%)
Apr 18, 2025, 3:30 PM JST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 18,726 employees as of March 31, 2024. The number of employees increased by 1,291 or 7.40% compared to the previous year.
Employees
18,726
Change (1Y)
1,291
Growth (1Y)
7.40%
Revenue / Employee
95.91M JPY
Profits / Employee
13.12M JPY
Market Cap
5,988.46B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 7,778 |
| Takeda Pharmaceutical Company | 49,281 |
| HOYA Corporation | 35,702 |
| Otsuka Holdings | 35,338 |
| Astellas Pharma | 14,754 |
| Olympus | 28,838 |
| Shionogi & | 4,959 |
| Sysmex | 10,042 |
Daiichi Sankyo Company News
- 7 days ago - Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha
- 10 days ago - Daiichi Sankyo and AstraZeneca get EU approval for Datroway - Seeking Alpha
- 14 days ago - European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings - Benzinga
- 18 days ago - DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer - Benzinga
- 4 weeks ago - Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
- 5 weeks ago - Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines - Business Wire
- 6 weeks ago - Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment - Seeking Alpha
- 6 weeks ago - ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial - Benzinga